Sammy Farah
Vorstandsvorsitzender bei TURNSTONE BIOLOGICS CORP.
Vermögen: - $ am 30.04.2024
Profil
Sammy J.
Farah is currently the President, Chief Executive Officer & Director at Turnstone Biologics Corp.
and the Chief Executive Officer at Myst Therapeutics LLC.
Previously, he worked as an Investment Professional at Versant Venture Management LLC, the Chief Business Officer at Immune Design Corp., and the President at Synthetic Genomics Vaccines, Inc. He holds a doctorate degree from Stanford University, an MBA and a doctorate degree from the University of Pennsylvania, and an undergraduate degree from the Massachusetts Institute of Technology.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
19.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Sammy Farah
Unternehmen | Position | Beginn |
---|---|---|
TURNSTONE BIOLOGICS CORP. | Vorstandsvorsitzender | 01.10.2015 |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Vorstandsvorsitzender | - |
Myst Therapeutics LLC
Myst Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Myst Therapeutics LLC is a privately held, pre-clinical stage biotechnology company based in Glendale, CA. Myst Therapeutics LLC focuses on the development and commercialization of novel cancer immunotherapy products that utilize a patient's own immune system to treat solid tumors. Myst is dedicated to improving adoptive cell therapies, particularly neoantigen enriched T cell therapies for solid tumors. By combining methods of identifying neoantigen reactive T cells with their proprietary technologies and expertise in cell therapy development and manufacturing, Myst aims to rapidly advance and commercialize innovative therapies for a wide range of advanced solid tumors. The CEO of the company is Sammy J. Farah. Myst Therapeutics was acquired by Turnstone Biologics, Inc. on January 20, 2021. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Sammy Farah
Unternehmen | Position | Ende |
---|---|---|
Synthetic Genomics Vaccines, Inc. | Präsident | 01.10.2015 |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Private-Equity-Analyst | 31.05.2010 |
IMMUNE DESIGN CORP | Corporate Officer/Principal | - |
Ausbildung von Sammy Farah
Stanford University | Doctorate Degree |
University of Pennsylvania | Doctorate Degree |
Massachusetts Institute of Technology | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
TURNSTONE BIOLOGICS CORP. | Health Technology |
Private Unternehmen | 5 |
---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Immune Design Corp.
Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Synthetic Genomics Vaccines, Inc. | |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Health Technology |
Myst Therapeutics LLC
Myst Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Myst Therapeutics LLC is a privately held, pre-clinical stage biotechnology company based in Glendale, CA. Myst Therapeutics LLC focuses on the development and commercialization of novel cancer immunotherapy products that utilize a patient's own immune system to treat solid tumors. Myst is dedicated to improving adoptive cell therapies, particularly neoantigen enriched T cell therapies for solid tumors. By combining methods of identifying neoantigen reactive T cells with their proprietary technologies and expertise in cell therapy development and manufacturing, Myst aims to rapidly advance and commercialize innovative therapies for a wide range of advanced solid tumors. The CEO of the company is Sammy J. Farah. Myst Therapeutics was acquired by Turnstone Biologics, Inc. on January 20, 2021. | Commercial Services |